Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H22N4O2 |
Molecular Weight | 326.3929 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C1=CN=C2NC=CC2=C1N[C@H]3[C@H]4CC5C[C@@H]3C[C@@](O)(C5)C4
InChI
InChIKey=DREIJXJRTLTGJC-RRBRBRQDSA-N
InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14-,18+
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28118538Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02308163 | https://clinicaltrials.gov/ct2/show/NCT02305849 | https://www.drugbank.ca/drugs/DB11708 | https://www.ncbi.nlm.nih.gov/pubmed/28118538 | https://www.ncbi.nlm.nih.gov/pubmed/26351728 | https://www.ncbi.nlm.nih.gov/pubmed/28117214
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28118538
Curator's Comment: The description was created based on several sources, including
https://clinicaltrials.gov/ct2/show/NCT02308163 | https://clinicaltrials.gov/ct2/show/NCT02305849 | https://www.drugbank.ca/drugs/DB11708 | https://www.ncbi.nlm.nih.gov/pubmed/28118538 | https://www.ncbi.nlm.nih.gov/pubmed/26351728 | https://www.ncbi.nlm.nih.gov/pubmed/28117214
Peficitinib (formerly known as ASP015K) is a pyrrolo[2,3-b]pyridine derivative orally administered once-daily JAK inhibitor in development for the treatment of Rheumatoid Arthritis. In preclinical studied Peficitinib inhibited JAK1 and JAK3 with IC50 of 3.9 and 0.7 nM, respectively. Peficitinib also inhibited IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo. Furthermore, Peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens.In clinical trials, Peficitinib treatment prescribed at 50, 100 and 150 mg amounts each showed statistically significantly higher ACR20 response rates compared to the placebo and response rates increased up to the 150 mg dosage. Adverse events included neutropenia, headache, and abdominal pain. The treatment-emergent adverse events occurring more frequently in the Peficitinib group compared with the placebo group included diarrhea, nasopharyngitis, and increased serum creatine phosphokinase activity. No cases of serious infections were reported. Herpes zoster occurred in four patients (two each in the peficitinib 25 and 100 mg cohorts). The authors concluded that treatment with peficitinib as monotherapy for 12 weeks in Japanese patients with moderate to severe RA is efficacious and showed an acceptable safety profile.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26351728 |
3.9 nM [IC50] | ||
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26351728 |
5.0 nM [IC50] | ||
Target ID: CHEMBL2148 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26351728 |
0.71 nM [IC50] | ||
Target ID: CHEMBL3553 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26351728 |
4.8 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28118538
25 mg, 50 mg, 100 mg, or 150 mg once daily for 12 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28117214
Splenocytes from male Lewis rats were suspended in RPMI1640 (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum and 50 mkM 2-mercaptoethanol at a density of 1.5 x 10^6 cells/mL. Rat splenocytes were cultured with Concanavalin A (Sigma) for 24 h at 37 C to induce IL-2 receptor expression. Splenocytes were then incubated with IL-2 (BD Biosciences, San Diego, CA, USA) and peficitinib or tofacitinib at designated concentrations in 96-well tissue culture plates. After 3-day incubation, alamarBlue® (Life Technologies, Carlsbad, CA, USA) was added to each of the test wells, followed by 4-6 h incubation. Fluorescence intensity was measured at an excitation wavelength of 545 nm and an emission wavelength of 590 nm.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
944118-01-8
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
AB-46
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
C170291
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
HPH1166CKX
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
100000170786
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
CHEMBL3137308
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
9910
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
DTXSID801319101
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
SUB184949
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY | |||
|
DB11708
Created by
admin on Sat Dec 16 01:28:11 GMT 2023 , Edited by admin on Sat Dec 16 01:28:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY